Detalles de la búsqueda
1.
Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial.
Clin Exp Nephrol
; 28(2): 153-164, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37910313
2.
Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
Clin Exp Nephrol
; 2024 Feb 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402503
3.
Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study.
Clin Exp Nephrol
; 28(3): 225-234, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37962746
4.
Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.
Nephrol Dial Transplant
; 38(5): 1204-1216, 2023 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36002026
5.
Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials.
Clin Exp Nephrol
; 27(8): 651-659, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37095342
6.
Target phosphate and calcium levels in patients undergoing hemodialysis: a post-hoc analysis of the LANDMARK study.
Clin Exp Nephrol
; 27(2): 179-187, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36303046
7.
Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial.
Clin Exp Nephrol
; 27(9): 757-766, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37289335
8.
A Comparative Study of Serum Phosphate and Related Parameters in Chronic Kidney Disease between the USA and Japan.
Am J Nephrol
; 53(2-3): 226-239, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35226897
9.
Estimating the causal effect of transient anemia status on renal and cardiovascular outcomes in community-dwelling patients in Japan at the beginning of impaired renal function using marginal structural modeling.
Clin Exp Nephrol
; 26(2): 178-189, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34596791
10.
Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial.
Clin Exp Nephrol
; 26(12): 1223-1232, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36064876
11.
Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat.
Clin Exp Nephrol
; 26(9): 843-850, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35462610
12.
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Am J Nephrol
; 52(10-11): 884-893, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34569482
13.
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Am J Nephrol
; 52(10-11): 871-883, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34569489
14.
Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
Am J Nephrol
; 52(6): 496-506, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34098559
15.
Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
Am J Nephrol
; 52(9): 702-713, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34628408
16.
Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.
Am J Nephrol
; 52(1): 26-35, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33561857
17.
Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial.
Nephrol Dial Transplant
; 36(6): 1088-1097, 2021 05 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32901255
18.
Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
Clin Exp Nephrol
; 25(1): 66-79, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32816132
19.
Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan.
Clin Exp Nephrol
; 25(2): 110-119, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32949295
20.
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
J Am Soc Nephrol
; 31(7): 1628-1639, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32493693